This trial will investigate the potential for patiromer-facilitated use of higher doses of
mineralocorticoid antagonists in addition to standard care (compared to standard care alone)
to improve congestion, well-being and mortality in people who have worsening congestion due
to heart failure and hyperkalaemia.